Welcome to the 4th Obesity & Weight Loss Drug Development Summit
The 4th Obesity & Weight Loss Drug Development Summit is the definitive forum to master the second wave of metabolic innovation. As the industry shifts from simple mass reduction to functional longevity, this summit is your strategic mandate to secure your position in a market where quality and differentiation are the sole commercial drivers.
We dive deep into the "Lean-Mass-First" paradigm, exploring how to decouple adipose reduction from skeletal muscle atrophy to ensure rapid weight loss translates into sustainable health. Attendees will navigate the high-stakes race between injectable peptides and next-gen oral small molecules, balancing peak potency with the long-term adherence required to dominate the maintenance market.
You will gain critical insights into the impact of genetics and proteomics on treatment response to identify high-responders and minimize trial attrition. Furthermore, we address the urgent need for age-specific clinical protocols tailored to the unique risks of pediatric and geriatric populations. Finally, collaborate to discuss how the regulatory landscape needs updating, to move beyond BMI to establish "High-Quality Weight Loss" as the new gold standard for clinical success.
Hear from industry giants including Novo Nordisk, Eli Lilly, and Merck & Co., alongside innovative biotechs, such as Metsera and Veru Inc.
Join your peers and forge the crucial collaborations defining the 2026 obesity pipeline.
Unmissable Event Highlights
Master the "Second Wave" of multi-agonist and combinatorial drug development and gain competitive insights on the next generation of triple-agonists (GLP-1/GIP/Glucagon) and novel combinations designed to shatter the 25% weight-loss ceiling.
Optimize clinical protocols for pediatric and geriatric populations to transition from "one-size-fits-all" dosing to age-specific precision. Engage in exclusive sessions focused on managing skeletal development in pediatric cohorts and preventing sarcopenia in geriatric patients, ensuring your assets meet the unique safety and metabolic requirements of the most vulnerable age groups.
Overcome the "Jab Fatigue" barrier with oral and long-acting innovation and join dedicated sessions focused on the high-stakes transition from weekly injectables to next-gen oral small molecules and once-monthly long-acting injectables to improve long-term patient adherence and capture the massive "maintenance" market.
Hear directly from the senior R&D leaders defining the 2026 pipeline. Gain access to first-hand clinical updates and strategic roadmaps from industry giants including Novo Nordisk and Eli Lilly alongside trailblazing biotechs like Metsera and Veru Inc. to benchmark against the titans of metabolic medicine.
Attending Companies Include
What to Expect:
Hear directly from 25+ senior expert speakers from pharma and biotech in the preclinical and clinical obesity drug development space, including Novo Nordisk, Eli Lilly, Roche, and Metsera as they provide first-hand perspectives on 2026 clinical readouts and the high-stakes race for the maintenance market.
Engage in two intensive pre-conference workshops that include 6+ hours of in-depth focus on leveraging genetics and proteomics to identify high-responders early in the pipeline and collaborating with the Veru Inc. to redefine clinical success beyond BMI through "High-Quality Weight Loss" metrics.
Connect with a focused delegation of senior drug developers in 7+ hours of networking with 120+ senior decision-makers leaders including the high-impact speed networking session designed to help you forge the strategic collaborations defining the future of global metabolic health.
Access more than 20 expert-led sessions and discussions dedicated to overcoming the next-generation obesity challenges with case studies addressing critical industry pivots, from muscle-preserving combination therapies to the transition toward next-gen oral small molecules and age-specific clinical protocols.
Explore the Full Event Guide
- Access 16+ hours of data-driven content and deep dive into two full days of scientific programming, featuring high-level case studies on triple-agonists, mitochondrial metabolism, and next-generation oral small molecules to define the 2026 obesity pipeline
- Learn more about 2 focused, practical workshops at the pre-conference day featuring hands-on sessions led by Veru Inc. and Canary Cure
- See the world-class faculty including senior leaders from Novo Nordisk, Eli Lilly, and Merck & Co., SixPeaks Bio, Metsera and Syntis Bio
- Find out how you can forge high-value partnerships with senior leaders during 6+ hours of networking
- Explore 7 core strategic pillars from optimizing multi-targeted portfolios to prioritizing muscle quality and functional longevity
Explore the Agenda
Hear the latest industry breakthroughs and gain exclusive insights during our packed agenda, interactive roundtables, and panel discussions.
Partner With Us
Position yourself alongside other leading solution providers to ensure your brand is at the heart of biopharma deals.
Join Biopharma Experts
Be part of the hottest conversations with like-minded attendees spanning all stages of drug development and make critical connections during our dedicated networking sessions.